Latest Period
Q1 2026
Security Snapshot
Crinetics Pharmaceuticals, Inc. - COMMON STOCK (CRNX) Institutional Ownership
CUSIP: 22663K107
13F Institutional Holders and Ownership History from Q3 2018 to Q1 2026
Institutions Reporting
240
Shares (Excl. Options)
122,775,115
Price
$36.32
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / COMMON STOCK
- Symbol
- CRNX on Nasdaq
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 122,775,115
- Total 13F value
- $4,457,216,657
- Portfolio coverage rank
- 0%
- Share change
- +9,904,325
- Value change
- +$303,492,553
- Number of holders
- 240
- Shares outstanding
- 105,000,216
- SEC-reported price per share
- $41.00
- Insider filing price
- $41.00
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- CRNX - Crinetics Pharmaceuticals, Inc. - COMMON STOCK is tracked under CUSIP 22663K107.
- 240 institutions reported positions in Q1 2026.
- 6 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 239 to 240 between Q4 2025 and Q1 2026.
- SEC-reported value moved from $5,195,621,593 to $4,457,216,657.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 240 institutions filings for Q1 2026.
Security key
22663K107
Latest holder period
Q1 2026
13F holders
240
13D/G owners
6
CIK / CUSIP context first
Open Q1 2026 holders
CRNX full holder history
Crinetics Pharmaceuticals, Inc. SEC filings
Crinetics Pharmaceuticals, Inc. company facts
Crinetics Pharmaceuticals, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 22663K107:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
6
Security
CRNX
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| FMR LLC | 15% | +46% | $466,033,211 | +$144,432,819 | 13,957,269 | +45% | FMR LLC | 31 Mar 2025 |
| WELLINGTON MANAGEMENT GROUP LLP | 7.8% | -12% | $321,720,126 | -$8,865,599 | 8,157,204 | -2.7% | Wellington Management Group LLP | 31 Mar 2026 |
| Farallon Capital Partners, L.P. | 8.5% | +42% | $373,521,762 | +$111,673,450 | 8,024,098 | +43% | Dapice Joshua J. | 31 Dec 2025 |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 6.1% | $252,255,164 | 6,395,922 | DRIEHAUS CAPITAL MANAGEMENT LLC | 31 Mar 2026 | |||
| VANGUARD CAPITAL MANAGEMENT LLC | 5.2% | $197,604,263 | 5,440,646 | Vanguard Capital Management | 31 Mar 2026 | |||
| PRICE T ROWE ASSOCIATES INC /MD/ | 5.1% | $211,201,634 | 5,355,011 | T. Rowe Price Associates, Inc. | 31 Mar 2026 |
As of 31 Mar 2026, 240 institutional investors reported holding 122,775,115 shares of Crinetics Pharmaceuticals, Inc. - COMMON STOCK (CRNX). This represents 117% of the company’s total 105,000,216 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
93%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| FMR LLC | 15% | 15,759,799 | +10% | 0.03% | $572,395,895 |
| BlackRock, Inc. | 8.1% | 8,478,815 | +6.1% | 0.01% | $307,950,573 |
| FARALLON CAPITAL MANAGEMENT LLC | 7.9% | 8,338,098 | +20% | 2% | $302,839,719 |
| WELLINGTON MANAGEMENT GROUP LLP | 7.8% | 8,157,204 | +1.5% | 0.06% | $296,269,650 |
| Driehaus Capital Management LLC | 6.1% | 6,395,922 | +0.13% | 1.7% | $232,299,887 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 5.1% | 5,355,496 | +2.5% | 0.02% | $194,513,000 |
| VANGUARD CAPITAL MANAGEMENT LLC | 4.5% | 4,673,935 | 0% | 0% | $169,757,319 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 4.4% | 4,638,511 | 0% | 0.01% | $168,470,720 |
| JANUS HENDERSON GROUP PLC | 4.3% | 4,520,251 | +1.8% | 0.08% | $164,227,195 |
| EcoR1 Capital, LLC | 4.1% | 4,288,120 | 0% | 6.7% | $155,744,518 |
| Bellevue Group AG | 3.1% | 3,280,000 | +81088% | 2.8% | $119,129,600 |
| GEODE CAPITAL MANAGEMENT, LLC | 2.4% | 2,480,763 | +11% | 0.01% | $90,119,429 |
| STATE STREET CORP | 2.3% | 2,403,046 | +11% | 0% | $87,278,631 |
| BAKER BROS. ADVISORS LP | 2.2% | 2,351,465 | +43% | 0.49% | $85,405,209 |
| T. Rowe Price Investment Management, Inc. | 1.8% | 1,940,622 | +3182% | 0.05% | $70,484,000 |
| Siren, L.L.C. | 1.8% | 1,903,636 | +26% | 1.9% | $69,140,060 |
| Pictet Asset Management Holding SA | 1.8% | 1,884,281 | +21% | 0.07% | $68,204,218 |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | 1.6% | 1,716,445 | +29% | 0.07% | $62,341,282 |
| GW&K Investment Management, LLC | 1.5% | 1,618,686 | +9.6% | 0.52% | $58,791,000 |
| NOVO HOLDINGS A/S | 1.5% | 1,550,000 | -4.6% | 4.6% | $56,296,000 |
| RTW INVESTMENTS, LP | 1.4% | 1,451,326 | +7.4% | 0.52% | $52,712,160 |
| JPMORGAN CHASE & CO | 1.3% | 1,324,668 | +15% | 0% | $45,396,372 |
| ADAR1 Capital Management, LLC | 1.1% | 1,139,331 | +268% | 2.5% | $41,380,502 |
| First Light Asset Management, LLC | 1% | 1,089,670 | -8.8% | 3.5% | $39,576,814 |
| AMERICAN CENTURY COMPANIES INC | 1% | 1,052,858 | -1.5% | 0.02% | $38,239,852 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
31
Latest
Q1 2026
Rows shown
1-25 of 31
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 122,775,115 | $4,457,216,657 | +$303,492,553 | $36.32 | 240 |
| 2025 Q4 | 111,610,559 | $5,195,621,593 | +$186,370,978 | $46.55 | 239 |
| 2025 Q3 | 107,709,232 | $4,486,288,734 | +$149,976,766 | $41.65 | 225 |
| 2025 Q2 | 104,559,713 | $3,007,383,972 | +$75,026,414 | $28.76 | 220 |
| 2025 Q1 | 101,790,412 | $3,418,305,905 | +$9,856,311 | $33.54 | 225 |
| 2024 Q4 | 99,690,161 | $5,097,004,672 | +$758,098,969 | $51.13 | 245 |
| 2024 Q3 | 84,525,573 | $4,321,960,073 | +$33,724,194 | $51.10 | 233 |
| 2024 Q2 | 82,487,807 | $3,694,594,767 | +$92,152,096 | $44.79 | 232 |
| 2024 Q1 | 80,384,076 | $3,762,661,947 | +$486,785,470 | $46.81 | 201 |
| 2023 Q4 | 70,656,199 | $2,513,959,167 | +$68,274,571 | $35.58 | 180 |
| 2023 Q3 | 68,535,017 | $2,038,114,354 | +$440,832,585 | $29.74 | 171 |
| 2023 Q2 | 54,057,835 | $974,084,774 | -$11,795,159 | $18.02 | 138 |
| 2023 Q1 | 55,062,782 | $884,310,368 | +$2,280,401 | $16.06 | 127 |
| 2022 Q4 | 54,817,398 | $1,003,122,430 | -$14,306,281 | $18.30 | 121 |
| 2022 Q3 | 51,456,378 | $1,010,816,996 | +$16,147,822 | $19.64 | 118 |
| 2022 Q2 | 50,645,843 | $944,532,132 | +$94,595,270 | $18.65 | 109 |
| 2022 Q1 | 45,482,453 | $997,426,956 | -$15,117,112 | $21.95 | 114 |
| 2021 Q4 | 44,273,322 | $1,256,550,441 | +$251,517,738 | $28.41 | 114 |
| 2021 Q3 | 33,632,624 | $708,150,662 | +$17,177,215 | $21.05 | 91 |
| 2021 Q2 | 32,726,853 | $616,933,642 | +$42,446,903 | $18.85 | 81 |
| 2021 Q1 | 30,730,499 | $465,273,247 | +$5,520,857 | $15.28 | 78 |
| 2020 Q4 | 30,426,213 | $429,299,885 | -$4,592,533 | $14.11 | 84 |
| 2020 Q3 | 30,337,604 | $475,397,972 | -$19,900,117 | $15.67 | 70 |
| 2020 Q2 | 31,451,376 | $546,085,663 | +$188,712,886 | $17.52 | 79 |
| 2020 Q1 | 20,679,487 | $303,862,789 | +$45,411,611 | $14.70 | 55 |